PF-07257876

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePF-07257876

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers

TargetsCluster of differentiation 47Programmed death-ligand 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsSquamous Cell Carcinoma of Head and Neck

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsSquamous Cell Carcinoma of Head and Neck

Inactive IndicationsN/A

Other Information

ATC CodeN/A